HC
ICPT

Henshaw Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Henshaw Capital’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,829
Closed -$227K – 326
2019
Q4 		$227K Buy
+1,829
New +$164K 0.02% 246

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Henshaw Capital's ICPT Position: Q1 2020 in Review

Henshaw Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2020, closing a stake of 1,829 shares — an estimated $227K sold.

Henshaw Capital first reported a position in ICPT in Q4 2019 and held it in 1 quarter. The position peaked at $227K in Q4 2019. 188 funds tracked by Wall St. Rank hold ICPT as of Q1 2020.

  • Henshaw Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Henshaw Capital sold 1,829 Intercept Pharmaceuticals, Inc. shares in Q1 2020, an estimated $227K.
  • Henshaw Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2019 and held it in 1 quarter.
  • Henshaw Capital's Intercept Pharmaceuticals, Inc. position peaked at $227K in Q4 2019.
  • 188 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2020.

Based on Henshaw Capital's 13F filing for Q1 2020, filed 28 May 2026.